Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.51), $0.03 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $185.6 million versus the consensus estimate of $192.89 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.